Show Notes
This episode introduces Talquetamab - a newly approved bispecific antibody for relapsed myeloma - explaining how it works, who it’s for, and what side effects patients should expect and prepare for. 📌Key Takeaways:
Talquetamab is a brand-new treatment targeting GPRC5D - offering another effective option after several previous therapies. Early side effects like fever, blood pressure changes or confusion are monitored closely and are almost always reversible. Taste changes, mouth soreness, skin issues and nail changes are common - but they can usually be managed so patients can stay on the treatment.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns
ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
More from The Myeloma Minutes
This episode explores the latest advances in myeloma treatment, explaining how the PERSEUS regimen combines four drugs, stem cell transplant and personalised maintenance to help patients achieve deeper, longer-lasting remissions. 📌Key Takeaways: Could remission last 10 years or more? Four drugs, better results - what has changed? Side effects matter: why your treatment can be adjusted.
Could the right treatment pace make all the difference to living well with myeloma? Professor Gordon Cook explores frailty in myeloma, explaining why it is more than age, how fitness can change during treatment, and why treatment should be tailored to the individual. 📌Key Takeaways: Frailty is dynamic - it can change. Age alone doesn't tell the whole story. Myeloma treatment isn't a sprint - it's a marathon.
This episode explores the realities of living with multiple myeloma, from treatment and managing symptoms to maintaining quality of life and finding confidence beyond the diagnosis. 📌Key Takeaways: Myeloma changes life - but it doesn’t have to define it. Small changes can make a big difference to wellbeing. You can still plan, adapt and look forward.
This episode explores the latest breakthroughs from the world's leading myeloma conferences, explaining how new research and clinical trials could shape future treatment and improve patient care with Charlotte. 📌Key Takeaways: Discover the newest treatments that could transform myeloma care in the years ahead. Find out why clinical trials today become tomorrow’s standard treatments. Hear how global collaboration is bringing safer, more effective therapies closer to patients.
This episode explains when DT-PACE chemotherapy is used in myeloma, how it works, what patients can expect during treatment, and why it remains an important bridge to newer therapies. 📌Key Takeaways: Why use older chemotherapy? Sometimes it's the fastest way to get myeloma back under control. DT-PACE is a bridge - helping patients reach treatments like stem cell transplant or CAR T-cell therapy. The treatment is intensive, but careful monitoring helps manage side effects and maximise its benefits.